COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 739.1 | 3 | 0003-0084 | 824.96 | 84.25 | 264 | 61.94 | 0.865 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 503.7 | 3 | 0004-0098 | 283.01 | 98.19 | 236 | 61.26 | 0.790 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 653.9 | 3 | 0005-0107 | 865.02 | 107.68 | 209 | 59.26 | 0.748 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 552.5 | 3 | 0006-0109 | 428.96 | 108.97 | 213 | 54.53 | 0.900 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 636.1 | 3 | 0007-0117 | 337.10 | 117.22 | 177 | 52.18 | 0.817 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 618.6 | 3 | 0008-0120 | 858.06 | 120.25 | 224 | 55.94 | 0.899 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 797.6 | 3 | 0009-0140 | 463.15 | 140.84 | 127 | 57.60 | 0.481 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 562.1 | 3 | 0010-0154 | 925.91 | 153.92 | 225 | 57.36 | 0.859 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 877.2 | 3 | 0011-0159 | 132.00 | 159.59 | 256 | 62.53 | 0.823 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 926.1 | 3 | 0012-0161 | 248.69 | 161.09 | 118 | 40.28 | 0.914 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 821.1 | 3 | 0013-0170 | 238.79 | 170.81 | 151 | 46.53 | 0.877 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 809.1 | 3 | 0014-0176 | 428.50 | 176.01 | 204 | 58.18 | 0.757 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 438.3 | 3 | 0015-0181 | 503.87 | 181.33 | 291 | 66.77 | 0.820 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 805.7 | 3 | 0016-0180 | 529.81 | 180.56 | 171 | 50.53 | 0.842 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 771.4 | 3 | 0017-0197 | 582.62 | 198.37 | 177 | 56.18 | 0.705 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 647.9 | 3 | 0018-0200 | 927.92 | 200.57 | 216 | 59.60 | 0.764 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 728.7 | 3 | 0019-0218 | 416.36 | 218.30 | 165 | 50.04 | 0.828 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 665.2 | 3 | 0020-0225 | 645.39 | 226.73 | 372 | 80.08 | 0.729 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 471.8 | 3 | 0021-0230 | 534.48 | 231.10 | 267 | 63.26 | 0.839 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 503.8 | 3 | 0022-0244 | 246.67 | 242.06 | 190 | 58.87 | 0.689 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 610.4 | 3 | 0023-0252 | 396.23 | 252.19 | 223 | 54.53 | 0.943 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 429.4 | 3 | 0024-0254 | 528.93 | 254.27 | 270 | 65.01 | 0.803 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 468.9 | 3 | 0025-0258 | 249.56 | 257.64 | 117 | 41.70 | 0.846 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 384.3 | 3 | 0026-0275 | 172.46 | 274.70 | 276 | 67.84 | 0.754 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 421.8 | 3 | 0027-0281 | 631.58 | 281.17 | 262 | 59.94 | 0.916 |